Advanced Search

Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2016 September;55(3) > Minerva Pneumologica 2016 September;55(3):37-54

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA PNEUMOLOGICA

A Journal on Diseases of the Respiratory System

Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus

Frequency: Quarterly

ISSN 0026-4954

Online ISSN 1827-1723

 

Minerva Pneumologica 2016 September;55(3):37-54

    REVIEWS

Pulmonary fibrosis: key features and challenges

Alessia FRACCARO 1, Elisabetta RENZONI 2, 3

1 Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy; 2 Interstitial Lung Disease Unit, Royal Brompton and Harefield NHS Trust, London, UK; 3 National Heart and Lung Institute, Imperial College London, London, UK

Interstitial lung diseases (ILDs) are a heterogeneous group of lung disorders with distinct clinical, radiological and morphological features. Among ILDs, idiopathic pulmonary fibrosis (IPF) is associated with the worst prognosis, with a survival worse than many cancers, even after the advent of two anti-fibrotic drugs, shown to halve disease progression. Reaching the correct diagnosis is crucial, as pathogenesis, prognosis and treatment options differ substantially from other interstitial fibrosing processes where immune overactivity plays a role in driving fibrosis. However, a subgroup of patients with fibrotic lung disease mediated by immune dysregulation can experience relentlessly progressive fibrosis despite immunosuppressive treatment, and behave similarly to IPF. It is clear that even in non IPF ILDs, phenotypes of relentlessly progressive disease exist, and molecular pathways may overlap. One of the main challenges for the future is the use of high throughput molecular biology techniques to stratify patients with progressive fibrotic lung disease, in order to identify genetic, epigenetic and protein markers to predict the individual patient’s rate of progression and fundamental molecular pathways involved. In this review, we will focus on the challenges in the diagnosis and management of idiopathic pulmonary fibrosis as well as differences and areas of overlap with other fibrotic ILDs, including fibrotic hypersensitivity pneumonitis, connective tissue disease-associated ILD and interstitial pneumonia with autoimmune features

language: English


FULL TEXT  REPRINTS

top of page